Search
Search Results
-
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for T-cell malignancies but is...
-
Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)
BackgroundThe survival rate for patients with relapsed and refractory acute myeloid leukaemia (R/R-AML) remains poor, and treatment is challenging....
-
Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma
Patients with relapsed/refractory early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) respond poorly to traditional therapy and have...
-
The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant
Upfront autologous stem cell transplant (ASCT) is the standard of care for newly diagnosed multiple myeloma (MM) patients. However, relapse is...
-
The correlation of next-generation sequencing-based genotypic profiles with clinicopathologic characteristics in NPM1-mutated acute myeloid leukemia
The purpose of this study was to analyze the association between next-generation sequencing (NGS) genotypic profiles and conventional...
-
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study
Acute myeloid leukemia (AML) with t(9;22) (q34.1; q11.2)/ BCR::ABL1 , a distinct entity within the group of AML with defining genetic abnormalities,...
-
-
CRISPR/Cas-based CAR-T cells: production and application
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the treatment approach for cancer, autoimmune disease, and heart disease. The...
-
Flow Cytometry in the Diagnosis of Hematological Neoplasms and Other Cancers
Flow cytometry (FCM) is a powerful technology that can provide rapid multiparameter analysis of single cells. With the significant improvement in...
-
Identification and Purification of Human T Cell Precursors
During their development, human T cells undergo similar genomic changes and pass through the same developmental checkpoints as develo** thymocytes...
-
Engineering Nanobody Targeting Cancer Stem Cells
Nanobodies (Nbs) are great molecular tools that can circumvent the limitations of traditional antibodies such as large size, low stability, slow...
-
Intrathymic dendritic cell-biased precursors promote human T cell lineage specification through IRF8-driven transmembrane TNF
The cross-talk between thymocytes and thymic stromal cells is fundamental for T cell development. In humans, intrathymic development of dendritic...
-
The Promise of Immunotherapeutics and Vaccines in the Treatment of Cancer
The Cancer Moonshot aspires to cut the death rate from cancer by at least 50% over the next 25 years by 2047 and improve the experience of people and...
-
-
Induction of Human T Cell Development In Vitro with OP9-DL4-7FS Cells Expressing Human Cytokines
For nearly a generation now, OP9-DL1 and OP9-DL4 cells have provided an efficient and reliable cell system to generate T cells from mouse and human...
-
In Vitro Model Systems to Study Human T Cell Development
Not only is human T cell development characterized by unique changes in surface marker expression, but it also requires specific growth factors and...
-
Biomarkers as targets for CAR-T/NK cell therapy in AML
The most common kind of acute leukemia in adults is acute myeloid leukemia (AML), which is often treated with induction chemotherapy regimens...
-
Therapeutic challenges in peripheral T-cell lymphoma
Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Compared to our knowledge of B-cell tumors, our...
-
The Promise of Immunotherapeutics and Vaccines in the Treatment of Cancer
The Cancer Moonshot aspires to cut the death rate from cancer by at least 50% over the next 25 years by 2047 and improve the experience of people and...
-
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma
T-lymphocytes are prevalent in the tumor microenvironment of follicular lymphoma (FL). However, the phenotype of T-cells may vary, and the prevalence...
